• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience

The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • collapse An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
  • collapse A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients with AD & HV
  • collapse An Open-label, Single-center Study to Assess the Pharmacokinetics of NKTR-118 in Patients with Impaired Hepatic Function and Subjects with Normal Hepatic Function Following Administration of a Single Dose of 25mg NKTR-118
  • collapse Investigating safety, tolerability and pk when giving single and fractionated doses of AZD3241 to healthy volunteers
  • collapse An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects with Renal Impairment and Subjects with Normal Renal Function
  • collapse A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for major depressive disorder
  • collapse A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo
  • collapse A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms with AZD8529 in Patients with Schizoph
  • collapse A Phase I, Open-Label, Single-Centre Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) after [14C]-labelled Oral Administration of NKTR-118 to Healthy Male Volunteers
  • collapse Seroquel acute manic
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013